Janus Henderson Investors US’s Vertex Pharmaceuticals VRTX Stock Holding History

Janus Henderson Investors US’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$44.8M	Sell	409,971 -15,606	-4%	-$1.37M	0.04%	469
2016 Q4	$31.4M	Sell	425,577 -60,172	-12%	-$4.9M	0.03%	530
2016 Q3	$42.4M	Sell	485,749 -90,210	-16%	-$8.53M	0.04%	454
2016 Q2	$49.5M	Sell	575,959 -322,707	-36%	-$27.9M	0.04%	427
2016 Q1	$71.4M	Sell	898,666 -124,364	-12%	-$11.2M	0.06%	351
2015 Q4	$129M	Sell	1,023,030 -67,915	-6%	-$8.2M	0.11%	232
2015 Q3	$114M	Buy	1,090,945 +107,199	+11%	+$13.8M	0.1%	251
2015 Q2	$121M	Buy	983,746 +257,218	+35%	+$32.4M	0.1%	275
2015 Q1	$85.7M	Buy	726,528 +246,796	+51%	+$29.6M	0.07%	338
2014 Q4	$57M	Buy	479,732 +19,900	+4%	+$2.24M	0.05%	423
2014 Q3	$51.6M	Sell	459,832 -32,106	-7%	-$3.06M	0.05%	407
2014 Q2	$46.6M	Sell	491,938 -224,941	-31%	-$15.8M	0.04%	430
2014 Q1	$50.7M	Buy	716,879 +33,085	+5%	+$2.62M	0.05%	394
2013 Q4	$50.8M	Sell	683,794 -1,726,138	-72%	-$120M	0.05%	388
2013 Q3	$183M	Sell	2,409,932 -2,676,803	-53%	-$213M	0.18%	151
2013 Q2	$406M	Buy	+5,086,735	New	+$375M	0.42%	57

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Investors US's VRTX Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Vertex Pharmaceuticals (VRTX) stake by 3.7% in Q1 2017, selling an estimated $1.37M and leaving 409,971 shares worth $44.8M. The position accounts for 0.04% of the portfolio, ranked #469.

Janus Henderson Investors US first reported a position in VRTX in Q2 2013 and has held it in 16 quarters since. The position peaked at $406M in Q2 2013. 522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

Janus Henderson Investors US held 409,971 shares of Vertex Pharmaceuticals worth $44.8M as of Q1 2017.
Janus Henderson Investors US sold 15,606 Vertex Pharmaceuticals shares in Q1 2017, an estimated $1.37M.
Vertex Pharmaceuticals made up 0.04% of Janus Henderson Investors US's portfolio in Q1 2017, its #469 holding.
Janus Henderson Investors US first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
Janus Henderson Investors US's Vertex Pharmaceuticals position peaked at $406M in Q2 2013.
522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.